Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment. This study links the soluble forms of RAGE (sRAGE and esRAGE) with clinical outcome of melanoma patients. Moreover, tissue expression of RAGE was analyzed using immunohistochemistry on two independent tissue microarrays (TMA) containing 35 or 257 primary melanomas, and 41 or 22 benign nevi, respectively. Serum concentrations of sRAGE and esRAGE were measured in 229 Stage III–IV patients using ELISA and plasma concentrations of sRAGE were analyzed in an independent second cohort with 173 samples of Stage I–IV patients. In this cohort, three well‐described SNPs in the RAGE gene were analyzed. RAGE protein expression was highly upregulated in primary melanomas compared to benign nevi in the two TMA (p < 0.001 and p = 0.005) as well as in sun‐exposed melanomas (p = 0.046). sRAGE and esRAGE were identified as prognostic markers for survival as diminished sRAGE (p = 0.034) and esRAGE (p = 0.012) serum levels correlated with poor overall survival (OS). Multivariate Cox regression analysis showed that diminished serum sRAGE was independently associated with poor survival (p = 0.009). Moreover, diminished sRAGE was strongly associated with impaired OS in the second cohort (p < 0.001). Multivariate Cox regression analysis including the investigated SNPs revealed an independent correlation of the two interacting promoter SNPs with impaired OS. In conclusion, the soluble forms of RAGE and variants in its genetic locus are prognostic markers for survival in melanoma patients with high risk for progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE Mediates a Novel Proinflammatory Axis
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80801-6 · Cited by 1,864
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 5×
“Interaction between RAGE and its ligands amplifies the proinflammatory response.(7) A soluble form of RAGE (sRAGE) is known to be generated by shedding via ADAM10 or by alternative splicing(9) and is abundant in plasma/serum of healthy persons, where it is thought to act as decoy for its ligands.”
BackgroundInfluentialBlockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
S100A8 and S100A9 in inflammation and cancer
Gebhardt, C., Németh, J., Angel, P., & Hess, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.05.017 · Cited by 696
Self-citationUltraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Bald, T., Quast, T., Landsberg, J., Rogava, M., Glodde, N., Lopez-Ramos, D., Kohlmeyer, J., Riesenberg, S., van den Boorn-Konijnenberg, D., Hömig-Hölzel, C., et al. (2014) · Nature · doi:10.1038/nature13111 · Cited by 623 · cited 3×
“Moreover, damage-associated molecular pattern molecules (DAMPs) and its receptors such as RAGE have gained further interest recently as the role of tumor-promoting inflammation has been identified as an attractive target of innovative anti-tumor therapies.(30,31) This study explores the importance of the DAMP receptor…”
BackgroundMethodInfluentialRage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383 · cited 1×
“The three single nucleotide polymorphisms (SNPs) -374T/A (rs1800624), -429T/C (rs1800625) and G82S (rs2070600) in the RAGE gene (AGER gene locus) were investigated because of either enhancing transcriptional activity (-374T/A and -429T/C) or showing enhanced ligand binding (G82S).(16,17) Human genomic DNA was obtained…”
MethodKang, R., Loux, T., Tang, D., Schapiro, N. E., Vernon, P., Livesey, K. M., Krasinskas, A., Lotze, M. T., & Zeh, H. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113865109 · Cited by 163
Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays
Hsieh, H.-L., Schäfer, B. W., Sasaki, N., & Heizmann, C. W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01190-2 · Cited by 151
Cited by
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Self-citationZhang, K., Anumanthan, G., Scheaffer, S., & Cornelius, L. A. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.05.035 · Cited by 39
Sun, Q., Novak, D., Hüser, L., Poelchen, J., Wu, H., Granados, K., Federico, A., Liu, K., Steinfass, T., Vierthaler, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33591 · Cited by 20
Self-citation
Metadata
- Authors
- Wagner, N. B., Weide, B., Reith, M., Tarnanidis, K., Kehrel, C., Lichtenberger, R., Pflugfelder, A., Herpel, E., Eubel, J., Ikenberg, K., Busch, C., Holland‐Letz, T., Naeher, H., Garbe, C., Umansky, V., Enk, A., Utikal, J., & Gebhardt, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2015-07-14
- Volume
- 137
- Issue
- 11
- Pages
- 2607-2617
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1495863028
- Cited by
- 34
- References
- 9
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.